drugset / Trial / NCT01079702

Everolimus and Capecitabine in Patients With Advanced Malignancy

NCT01079702

Non-randomizedSingle-groupOpen-labelTreatment

Summary

In the investigators study the investigators combine everolimus, administrated twice daily at a fixed total dose of 10 mg continuously with capecitabine administered bid for 14 days followed by 7 days rest. In this study, capecitabine will be dose escalated.

Timeline

Start
2008-04
Primary completion
2010-04
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 500 mg/m2
Subject Everolimus Small molecule 10 mg Oral

Indications